Quarterly ResultJun 2, 2026, 04:06 PM
PetMeds FY26 Net Sales $179M (-21.1%); Net Loss $(57.3)M
AI Summary
PetMed Express reported a net loss of $57.3 million, or $(2.74) per diluted share, on net sales of $179.0 million for fiscal year 2026, a 21.1% decrease from the prior year. For the fourth quarter, net sales decreased 15.6% to $42.8 million, with a net loss of $4.1 million. The company also announced its Board decided not to proceed with two unsolicited acquisition proposals ranging from $4.00 to $4.25 per share, opting to continue as an independent public company while remaining open to future offers.
Key Highlights
- FY26 net sales decreased 21.1% to $179.0 million from $227.0 million.
- FY26 net loss was $57.3 million, or $(2.74) per diluted share.
- Q4 FY26 net sales decreased 15.6% to $42.8 million from $50.8 million.
- Q4 FY26 net loss was $4.1 million, or $(0.19) per diluted share.
- FY26 Adjusted EBITDA was $(15.4) million, down from $0.7 million in prior year.
- Board rejected two unsolicited acquisition proposals ($4.00-$4.25/share).
- Goodwill impairment charge of $26.7 million recorded in Q1 FY26.
- Cash and cash equivalents decreased to $21.4 million from $54.7 million.
Price Impact
More from PETS